Wang Xiaoyi resigned as chief executive officer and chief research officer of BrainAurora Medical Technology (HKG:6681), effective June 19, a Friday filing to the Hong Kong bourse said.
Wang cited deteriorating health due to depression linked to the company's listing process as the reason for his departure, according to the filing.
Cai Longjun, currently chief technology officer and chief operating officer, has been appointed to act as CEO and CRO with immediate effect.
He will also assume legal and managerial responsibilities across BrainAurora's subsidiaries previously held by Wang.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。